E
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.79
-$0.025-1.38%
E
Sell
6/20/2024Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index and total return index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 6/20/2024 due to a decline in the volatility index and total return index.
D
Sell
6/4/2024Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index.
E
Sell
5/17/2024Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index, total return index and valuation index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/2/2024Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 5/2/2024 due to an increase in the volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 5/2/2024 due to an increase in the volatility index.
E
Sell
4/17/2024Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index and total return index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index and total return index.
D
Sell
3/15/2024Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 3/15/2024 due to an increase in the volatility index and total return index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 3/15/2024 due to an increase in the volatility index and total return index.
E
Sell
2/29/2024Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 2/29/2024 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 8.77 to 6.96, earnings per share declined from -$0.7864 to -$0.86, and EBIT declined 8.3% from -$62.72M to -$67.92M.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 2/29/2024 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 8.77 to 6.96, earnings per share declined from -$0.7864 to -$0.86, and EBIT declined 8.3% from -$62.72M to -$67.92M.
D
Sell
2/8/2024Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 2/8/2024 due to an increase in the volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 2/8/2024 due to an increase in the volatility index.
E
Sell
1/24/2024Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 1/24/2024 due to a large decline in the total return index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 1/24/2024 due to a large decline in the total return index and volatility index.
D
Sell
8/4/2023Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 8/4/2023 due to a noticeable increase in the total return index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D- from E+ on 8/4/2023 due to a noticeable increase in the total return index and volatility index.
E
Sell
5/16/2023Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 5/16/2023 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 32.02% from -$37.33M to -$49.28M, EBIT declined 25.5% from -$51.75M to -$64.95M, and earnings per share declined from -$0.9456 to -$1.0665.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D- on 5/16/2023 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 32.02% from -$37.33M to -$49.28M, EBIT declined 25.5% from -$51.75M to -$64.95M, and earnings per share declined from -$0.9456 to -$1.0665.
D
Sell
3/14/2023Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 12.44% from -$33.2M to -$37.33M.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 12.44% from -$33.2M to -$37.33M.
D
Sell
2/23/2023Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 02/23/2023.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and total return index. The quick ratio declined from 9.36 to 7.8.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and total return index. The quick ratio declined from 9.36 to 7.8.
D
Sell
8/12/2022Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 8/12/2022 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 6.65 to 9.36, and operating cash flow increased 14.28% from -$50.2M to -$43.03M.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 8/12/2022 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 6.65 to 9.36, and operating cash flow increased 14.28% from -$50.2M to -$43.03M.
D
Sell
7/15/2022Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 7/15/2022 due to a decline in the total return index, valuation index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 7/15/2022 due to a decline in the total return index, valuation index and volatility index.
D
Sell
6/30/2022Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 6/30/2022 due to a noticeable increase in the total return index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 6/30/2022 due to a noticeable increase in the total return index and volatility index.
D
Sell
6/15/2022Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 6/15/2022 due to a decline in the total return index, valuation index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 6/15/2022 due to a decline in the total return index, valuation index and volatility index.
D
Sell
5/31/2022Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 05/31/2022.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 05/31/2022.
D
Sell
5/13/2022Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 7.73 to 6.65.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 7.73 to 6.65.
D
Sell
4/21/2022Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0939 to -$1.113, and operating cash flow declined 10.54% from -$33.49M to -$37.02M.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0939 to -$1.113, and operating cash flow declined 10.54% from -$33.49M to -$37.02M.
D
Sell
11/11/2021Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 11/11/2021 due to an increase in the growth index, solvency index and total return index. Earnings per share increased from -$1.3396 to -$0.0939, operating cash flow increased 27.37% from -$46.11M to -$33.49M, and the quick ratio increased from 7.47 to 9.31.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D from D- on 11/11/2021 due to an increase in the growth index, solvency index and total return index. Earnings per share increased from -$1.3396 to -$0.0939, operating cash flow increased 27.37% from -$46.11M to -$33.49M, and the quick ratio increased from 7.47 to 9.31.
D
Sell
11/8/2021Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and valuation index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index and valuation index.
D
Sell
10/1/2021Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from D+ on 10/1/2021 due to a decline in the volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from D+ on 10/1/2021 due to a decline in the volatility index.
D
Sell
9/15/2021Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D+ from D on 9/15/2021 due to a noticeable increase in the total return index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D+ from D on 9/15/2021 due to a noticeable increase in the total return index and volatility index.
D
Sell
8/13/2021Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from D+ on 8/13/2021 due to a decline in the total return index and volatility index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from D+ on 8/13/2021 due to a decline in the total return index and volatility index.
D
Sell
8/5/2021Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D+ from D on 8/5/2021 due to an increase in the total return index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D+ from D on 8/5/2021 due to an increase in the total return index.
D
Sell
7/14/2021Downgrade
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from D+ on 7/14/2021 due to a decline in the total return index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from D+ on 7/14/2021 due to a decline in the total return index.
D
Sell
6/29/2021Upgraded
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D+ from D on 6/29/2021 due to a large increase in the total return index and growth index.
Zentalis Pharmaceuticals, Inc. (ZNTL) was upgraded to D+ from D on 6/29/2021 due to a large increase in the total return index and growth index.
D
Sell
8/14/2020None
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from U on 08/14/2020.
Zentalis Pharmaceuticals, Inc. (ZNTL) was downgraded to D from U on 08/14/2020.
NASDAQ
03/14/2025 1:02PM Eastern
Quotes delayed
